Outcome of radiotherapy for low-risk early-stage patients with extranodal NK/T-cell lymphoma, nasal-type
10.3760/cma.j.cn112152-20200924-00851
- VernacularTitle:早期低危结外鼻型NK/T细胞淋巴瘤放疗的疗效
- Author:
Xiaodan WANG
1
;
Xin LIU
;
Tao WU
;
Yong YANG
;
Shunan QI
;
Xia HE
;
Liling ZHANG
;
Gang WU
;
Baolin QU
;
Liting QIAN
;
Xiaorong HOU
;
Fuquan ZHANG
;
Xueying QIAO
;
Hua WANG
;
Gaofeng LI
;
Yuan ZHU
;
Jianzhong CAO
;
Junxin WU
;
Suyu ZHU
;
Mei SHI
;
Hang SU
;
Ximei ZHANG
;
Huilai ZHANG
;
Huiqiang HUANG
;
Yujing ZHANG
;
Yuqin SONG
;
Jun ZHU
;
Ying WANG
;
Yexiong LI
Author Information
1. 国家癌症中心 国家肿瘤临床医学研究中心 中国医学科学院北京协和医学院肿瘤医院放疗科 100021
- Keywords:
Extranodal nasal-type NK/T-cell lymphoma;
Low risk early-stage;
Radiotherapy;
Prognosis
- From:
Chinese Journal of Oncology
2021;43(10):1105-1113
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the prognosis and determine the failure patterns after radiotherapy for low-risk early-stage patients with extranodal NK/T-cell lymphoma, nasal-type (ENKTCL).Methods:A total of 557 patients from 2000—2015 with low-risk early-stage ENKTCL who received radiotherapy (RT) with or without chemotherapy (CT) from China Lymphoma Collaborative Group were retrospectively reviewed. Among them, 427 patients received combined modality therapy, whereas 130 patients received RT alone. Survivals were calculated by Kaplan-Meier method and compared with Log-rank test. Overall survival (OS) was compared with age and sex-matched general Chinese population using expected survival and standardized mortality ratio (SMR). Cox stepwise regression model was used for multivariate analysis.Results:The 5-year OS and progression-free survival (PFS) were 87.2% and 77.2%. The SMR was 3.59 ( P<0.001) at 1 year after treatment, whereas it was 1.50 at 4 years after treatment, without significant difference between ENKTCL group and country-matched general population ( P=0.146). Compared with RT alone, CMT did not result in significantly superior 5-year OS (87.0% vs 87.4%, P=0.961) or PFS (76.1% vs 80.7%, P=0.129). Local failure (11.5%, 64/557) and distant failure (10.8%, 60/557) were the main failure modes, while regional failure was rare (2.9%, 16/557). The 5-year locoregional control rate (LRC) was 87.2% for the whole group, with 89.5% for ≥50 Gy versus 73.7% for <50 Gy ( P<0.001). Radiotherapy dose was an independent factor affecting LRC( P<0.05). Conclusions:Radiotherapy achieves a favorable prognosis in patients with low-risk early-stage ENKTCL. The incidence of either locoregional or distant failure is low. Radiation dose still is an important prognostic factor for LRC.
